Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)

NCT ID: NCT02194595

Last Updated: 2022-04-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 105 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-09-30
• Study Completion Date: 2022-02-28

Brief Summary

Type 2 diabetes mellitus is a chronic metabolic disorder characterized by progressive deterioration in the function of the pancreatic beta-cells, which are the cells that produce and secrete insulin (the hormone primarily responsible for the handling of glucose in the body). The investigators propose a randomized controlled trial to determine whether combining basal insulin with a new medication called exenatide is a therapeutic strategy that can preserve beta-cell function early in the course of type 2 diabetes.

Detailed Description

In this open-label, parallel-arm randomized controlled trial, adults with T2DM of ≤7 years duration on 0-2 anti-diabetic medications will be randomized to 8-weeks treatment with either (i) basal insulin glargine, (ii) intensive insulin therapy consisting of glargine and pre-meal insulin lispro, or (iii) glargine and the GLP-1 agonist exenatide (twice daily). They will then go into a 12-week washout on lifestyle modification only. Beta-cell function will be assessed by determining the Insulin Secretion-Sensitivity Index-2 (ISSI-2) on oral glucose tolerance test (OGTT) performed at baseline, 4-weeks, 8-weeks, and 20-weeks. The primary outcome will be mean beta-cell function (ISSI-2) over the 8-week treatment period.

Conditions

Type 2 Diabetes

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Basal insulin and exenatide

Participants in this arm will undergo an 8-week course of treatment with exenatide and insulin glargine. Exenatide will be initiated at 5ug subcutaneous (sc) bid (before breakfast and before dinner) for the first 4 weeks, followed by 10ug bid for the next 4 weeks. Glargine sc injection at bedtime will be titrated to fasting glucose.

Group Type: EXPERIMENTAL

Basal insulin and exenatide

Intervention Type: DRUG

Basal insulin only

Participants in this arm will undergo an 8-week course of treatment with glargine sc injection at bedtime, titrated to target fasting glucose.

Group Type: ACTIVE_COMPARATOR

Basal insulin only

Intervention Type: DRUG

Basal Insulin and bolus insulin

Participants in this arm will undergo an 8-week course of multiple daily insulin injection therapy, consisting of titrated basal insulin glargine at bedtime and insulin lispro before each meal.

Group Type: ACTIVE_COMPARATOR

Basal insulin and bolus insulin

Intervention Type: DRUG

Interventions

Basal insulin and exenatide

Intervention Type: DRUG

Basal insulin only

Intervention Type: DRUG

Basal insulin and bolus insulin

Intervention Type: DRUG

Other Intervention Names

Basal insulin glargine; Exenatide; Basal insulin glargine; Basal insulin glargine; Pre-meal insulin lispro

Eligibility Criteria

Inclusion Criteria

1. Men and women between the ages of 30 and 80 years inclusive

2. T2DM diagnosed by a physician ≤7 years prior to enrolment

3. On 0-2 anti-diabetic medications, with no change in dose/regimen in the preceding 4 weeks

4. A1c at screening between 5.5% and 9.0% inclusive if on anti-diabetic medications, or between 6.0% and 9.5% inclusive if on no oral anti-diabetic medication

5. BMI ≥ 23 kg/m2

6. Negative pregnancy test at recruitment for all women with childbearing potential

Exclusion Criteria

1. Current anti-diabetic treatment with insulin or a glucagon-like peptide-1 (GLP-1) agonist

2. Type 1 diabetes or secondary forms of diabetes

3. History of hypoglycemia unawareness or severe hypoglycemia requiring assistance

4. Hypersensitivity to insulin, exenatide, or the formulations of these products

5. Renal dysfunction as evidenced by estimated glomerular filtration rate (eGFR)<30 ml/min by Modification of Diet in Renal Disease (MDRD) formula

6. History of pancreatitis

7. Family or personal history of Multiple Endocrine Neoplasia type 2 (MEN-2) or familial medullary thyroid carcinoma (MTC)

8. Personal history of non-familial medullary thyroid carcinoma (MTC)

9. Malignant neoplasm requiring chemotherapy, surgery, radiation or palliative therapy within the previous 5 years (with the exception of basal cell skin cancer)

10. Unwillingness to perform capillary glucose monitoring at least 4 times a day during treatment

11. Pregnancy or unwillingness to use reliable contraception. Women should not be planning pregnancy for the duration of the study or the first 3 months after the study. Reliable contraception includes birth control pill, intra-uterine device, abstinence, tubal ligation, partner vasectomy, or condoms with spermicide.

12. Any factor likely to limit adherence to the protocol, in the opinion of investigator

• Minimum Eligible Age: 30 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

Sponsor Role: collaborator

University of Toronto

OTHER

Sponsor Role: collaborator

Mount Sinai Hospital, Canada

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ravi Retnakaran, MD

Role: PRINCIPAL_INVESTIGATOR

MOUNT SINAI HOSPITAL

Locations

Mount Sinai Hospital

Toronto, Ontario, Canada

Countries

Canada

References

Retnakaran R, Pu J, Ye C, Emery A, Kramer CK, Zinman B. The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes. Cardiovasc Diabetol. 2023 Mar 9;22(1):50. doi: 10.1186/s12933-023-01781-z.

Reference Type: DERIVED

PMID: 36894921 (View on PubMed)

Other Identifiers

14-0128-A

Identifier Type: -

Identifier Source: org_study_id